CNS EFFICACY OF ANTIOXIDANTS FROM PLANTS

描述(摘自申请者摘要)：中枢神经 中枢神经系统(CNS)似乎特别容易受到氧化应激的影响 被认为是神经退行性变的主要因素之一。这个 导致氧化应激的活性氧物种(ROS)一直是 与几种中枢神经系统功能障碍的病因有关，包括 帕金森氏症、亨廷顿病、阿尔茨海默病与老年人 大脑。ROS的形成和扩散可被延缓或抑制 可能来自内源性或外源性的抗氧化剂。一个 从植物中提取的许多物质已被证明具有 显著的抗氧化活性，因此具有潜在的直接或 间接应用于神经退行性疾病的治疗。在……里面 在我们项目的第一阶段，我们已经开发了半准备的方法 人参皂苷的提取、含量测定及体外生物测定 五种抗氧化剂，即胡萝卜中的β-胡萝卜素，胡萝卜中的叶黄素 香菜，番茄酱中的番茄红素，以及姜黄素和姜黄素 姜黄。在该项目的第二阶段，我们建议解决以下问题 问题：1)制定每个项目的商业准备程序 这些化合物中纯的形式和以良好的产率，使用最少的 昂贵的仪器和技术；2)扩大化验 单项及其混合物(鸡尾酒)的生物活性 抗氧化剂要在体内条件下才能补充体外 已经在第一阶段开发的方法；以及3)开发特定的 抗叶黄素、姜黄素和姜黄素的单抗。 建议的商业应用：不可用

DESCRIPTION (Adapted from Applicant's Abstract): The central nervous system (CNS) appears to be especially vulnerable to oxidative stress which is believed to be one of the major factors in neural degeneration. The reactive oxygen species (ROS) which cause the oxidative stress, have been implicated in the etiology of several CNS malfunctions, including Parkinsonism, Huntington's Disease, Alzheimer's Disease and aging of brain. The formation and spread of ROS may be delayed or inhibited by antioxidants which may be of either endogenous or exogenous origin. A number of substances derived from plants have been shown to possess significant antioxidant activity and, therefore, have potential direct or indirect applications in the treatment of neurodegenerative diseases. In Phase I of our project, we have developed methods for the semipreparative extraction, quantitative determination and in vitro biological assays of five plan antioxidants, viz., beta-carotene from carrots, lutein from parsley, lycopene form tomato paste, and curcumin and turmerin from turmeric. In Phase II of the project, we propose to address the following issues: 1) to develop procedures for the commercial preparation of each of these compounds in pure form and in good yield, using the least expensive instrumentation and technology; 2) to extend the assay of biological activities of individual and mixtures (cocktails) of these antioxidants to in vivo conditions so as to complement the in vitro methods already developed in Phase I; and 3) to develop specific monoclonal antibodies against lutein, curcumin and turmerin. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE